Company Overview
Dimerix is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using its innovative receptor technology to identify and develop drugs in areas with an unmet need.
Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment, DMX-200, that may transform the lives of patients with Kidney Disease. Dimerix has also recently developed other potential drugs in its pipeline, including DMX-700 for chronic obstructive pulmonary disease (COPD).
